Traitement en cours

Veuillez attendre...

Paramétrages

Paramétrages

Aller à Demande

1. WO2004069175 - METHODES ET COMPOSITIONS DE TRAITEMENT DE LA MALADIE DE PARKINSON ET D'AUTRES $G(A)-SYNUCLEINOPATHIES

Numéro de publication WO/2004/069175
Date de publication 19.08.2004
N° de la demande internationale PCT/US2004/002724
Date du dépôt international 30.01.2004
CIB
A61K 38/00 2006.1
ANÉCESSITÉS COURANTES DE LA VIE
61SCIENCES MÉDICALE OU VÉTÉRINAIRE; HYGIÈNE
KPRÉPARATIONS À USAGE MÉDICAL, DENTAIRE OU POUR LA TOILETTE
38Préparations médicinales contenant des peptides
CPC
A61K 31/13
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
A61K 31/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
13Amines
145having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
A61K 31/165
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
16Amides, e.g. hydroxamic acids
165having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/4172
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
41641,3-Diazoles
4172Imidazole-alkanecarboxylic acids, e.g. histidine
A61K 38/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
06Tripeptides
A61K 38/07
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
07Tetrapeptides
Déposants
  • GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES [US]/[US] (AllExceptUS)
  • MOURADIAN, M., Maral [US]/[US] (UsOnly)
  • JUNN, Eunsung [US]/[US] (UsOnly)
Inventeurs
  • MOURADIAN, M., Maral
  • JUNN, Eunsung
Mandataires
  • ROSENFIELD, Jennifer, K.
Données relatives à la priorité
60/444,56302.02.2003US
Langue de publication Anglais (en)
Langue de dépôt anglais (EN)
États désignés
Titre
(EN) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PARKINSON’S DISEASE AND OTHER &agr;-SYNUCLEINOPATHIES
(FR) METHODES ET COMPOSITIONS DE TRAITEMENT DE LA MALADIE DE PARKINSON ET D'AUTRES $G(A)-SYNUCLEINOPATHIES
Abrégé
(EN) The present invention provides novel methods for the treatment of Parkinson’s disease and other &agr;-synucleinopathies. The methods of the invention include treatment with inhibitors of transglutaminase, which can inhibit aggregation of &agr;-synuclein. Also provided are screening assays for novel inhibitors of transglutaminase which may be used in the treatment of Parkinson’s disease and other &agr;-synucleinopathies.
(FR) La présente invention concerne de nouvelles méthodes de traitement de la maladie de Parkinson et d'autres $g(a)-synucléinopathies. Les méthodes de traitement de l'invention consistent à utiliser des inhibiteurs de la transglutaminase, pouvant inhiber l'agrégation de la $g(a)-synucléine. L'invention concerne également des analyses de criblage de nouveaux inhibiteurs de la transglutaminase, pouvant être utilisés dans le traitement de la maladie de Parkinson et d'autres $g(a)-synucléinopathies.
Documents de brevet associés
Dernières données bibliographiques dont dispose le Bureau international